Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-2217-6821
New Synthesis of 3-Aminohydantoins via Condensation of Hydrazines with Isocyanates Derived from α-Amino Esters
Abstract
A new, simple, and efficient method for the synthesis of 3-aminohydantoins was reported in two steps, starting from the corresponding l -amino esters. Commercially available α-amino esters were converted into the corresponding isocyanate derivatives, which were then subjected to the condensation reaction with hydrazine hydrate and arylhydrazines, in the presence of DMAP and DIPEA. This method provides the corresponding 3-aminohydantoins in moderate and good yields under a simple and practical protocol.
#
Hydantoins or 1,3-imidazolidin-2,4-diones are five-membered nitrogen heterocycles that display a wide range of biological activities, some of them being used as efficient drugs for various pathologies.[1] [2] [3] [4] [5] In particular, 3-aminohydantoin derivatives are very promising compounds in the field of medicinal chemistry.[6–9] Indeed, several molecules containing the aminohydantoin moiety are endowed with various biological activities and have proven to be effective in the treatment of a large array of diseases (Figure [1]).[5] [6] [7] [8] [9] [10] In a recent study, we reported the 3-amino-5-benzylimidazolidine-2,4-dione (3-aminohydantoin derived from phenyl alanine) as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson’s disease.[11] We believe that 3-aminohydantoins are still understudied in medicinal chemistry. This probably arises from the methods of preparation of these compounds, which are not sufficiently developed to make these molecules easily available.[1]
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_f1_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Despite the simplicity of the chemical structure of 3-aminohydantoins and their importance as promising scaffolds and bioactive molecules, only few methods describing their synthesis have been reported in the literature. In 1985, Lalezari et al. reported a one-step synthesis of 3-aminohydantoins via the condensation of α-aminoacids with tert-butyl hydrazinecarboxylate in the presence of quinoline as the solvent and base. This method requires heating at an elevated temperature (240 °C) during 3–10 h.[12] [13] Yousong et al. described a seven-step synthesis of substituted 3-aminohydantoin derivatives, starting from an aldehyde and diethylmalonate. The synthesis involves an isocyanate as an intermediate, which is further reacted with an arylhydrazine. An intramolecular cyclization, in the presence of metallic sodium and ethanol affords the corresponding hydantoin.[14] Hamuro et al. disclosed a five-step solid-phase synthesis of 3-aminohydantoins from amino acids using Phoxime resin.[15] Janda et al. also described a six-step soluble-polymer-supported synthesis of 3-aminohydantoins from amino acids.[16] More recently, Beauchemin et al. developed a cascade synthesis of 3-aminohydantoins using α-amino esters and N-substituted isocyanates.[10] These methods have some drawbacks, such as harsh reaction conditions, in some cases low yields, multistep synthesis, and above all the nonavailability of the reagents used in these reactions especially for the last three methods.[10] [15] [16] We believe that more economical and practical methods, using more available and less expensive reagents, to easily access 3-aminohydantoins are still needed.
In this work, we developed a new method for the easy access to 3-aminohydantoins using available and inexpensive reagents under relatively mild conditions. This method involves firstly preparing isocyanate derivatives from l-amino esters, and, secondly, reacting these isocyanates with hydrazine hydrate and aromatic hydrazines in the presence of diisopropyl ethylamine (DIPEA, 3 equiv.) and dimethyl aminopyridine (DMAP, 0.2 equiv.) in dimethyl sulfoxide (DMSO) as the solvent to provide 3-aminohydantoin derivatives (Scheme [1]).
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s1_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s2_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Initially, commercially available α-amino esters 1a–f were converted into the corresponding isocyanate derivatives 2a–f according to a literature method (Scheme [1]).[17] [18] Triphosgene (bis(trichloromethyl)carbonate, BTC) reacted with the amine group of the α-amino ester in biphasic medium (50:50 CH2Cl2/sat. aq. NaHCO3) to provide quantitatively the corresponding isocyanate, which was used in the next step without purification. All isocyanate derivatives 2a–f prepared in this work are known compounds.[19] [20] [21] In the second step, isocyanates 2a–f were reacted with (aryl)hydrazine to afford the corresponding 3-aminohydantoins (Scheme [2]).[22]
Hydantoins 3 and 4 were prepared using different reaction conditions, i.e., temperature and reaction time (Scheme [2]). This is probably due to the difference between the reactivity of hydrazine as the nucleophile and that of arylhydrazines. Indeed, it was found that the reaction of isocyanates with hydrazine hydrate requires heating up to 100 °C for 0.5 h to provide the corresponding 3-aminohydantoins 3 with moderate to good yields. However, the reaction of arylhydrazines requires a higher temperature (120 °C) and a longer reaction time (8 h) to provide the corresponding 3-aminohydantoins 4 with satisfactory yields. Notably, only a low yield of the product was obtained when 3-amino-5-benzylimidazolidine-2,4-dione was heated at 150 °C without using DMAP.[5] In this work, we prepared a series of fourteen 3-aminohydantoins. 3-Aminohydantoins 3a–e possessing an NH2 group linked to N-3 of the heterocycle were isolated in 45–89% yields, whereas substituted hydantoins 4a–i on the N-3 atom of the cycle were obtained in 29–79% isolated yields. While l-amino esters were used as precursors, we found that all synthesized 3-aminohydantoins were obtained in the racemic form. This was confirmed by measuring their optical rotation ([α]D = 0 in all cases). This result is somewhat expected, since Beauchemin et al. obtained the same result when they prepared 3-aminohydantoins following their procedure, which required heating to 100 °C.[10]
Firstly, the addition of the hydrazine on the isocyanate group leads to the noncyclic intermediate (Scheme [3]). Subsequently, by heating the reaction mixture at the appropriate temperature, the cyclization occurred by attack of the nitrogen atom on the ester function. We found that the use of the DIPEA (3 equiv.)/DMAP (0.2 equiv.) system was necessary to ensure product formation. Without using this basic system, significantly lower yields of 3-aminohydantoins were obtained.[5] Apparently, the basic system facilitates the transfer of the proton linked to nitrogen which attacks the ester during the cyclization step. In order to confirm the proposed mechanism, we isolated the intermediate formed by the reaction between phenylhydrazine and isocyanate 2a after stirring for 0.5 h at 0 °C and before subjecting the reaction mixture to heating. Both 1H and 13C NMR data of the obtained intermediate are in agreement with the proposed structure of the intermediate I highlighted in Scheme [3] (see the Supporting Information).
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s3_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
We believe that our method for the synthesis of 3-aminohydantoins, described in this work, has several advantages over those described in the literature for the following reasons. (i) Nakamura et al. described the synthesis of 3-aminohydantoins 3c and 3d as precursors to prepare new useful molecules for the treatment of Alzheimer’s desease.[8] These authors used the method of Lalezari et al.,[12] which provided the 3-aminohydantoins in 10% and 23%, yields respectively. The same 3-aminohydantoins were prepared using our method under milder conditions and with higher yields (3c: 89%, 3d: 45%; Scheme [2]). (ii) Janda et al. prepared 3-aminohydantoins 3a, 3b, and 3c in six steps starting from the corresponding amino esters.[16] The chemical yields obtained using their method are in the 60–67% yield range, whereas our method provided the same 3-aminohydantoins in steps with 46–89% yields (3a: 45%, 3b: 76%, 3c: 89%). (iii) Hamuro et al. [15] reported a five-step procedure to prepare 3-aminohydantoins 4a and 4d in 47% and 34% yields, respectively, starting from the corresponding amino acids. In this work, 3-aminohydantoins 4a and 4d were obtained in two steps with 35% and 79% yields, respectively. (iv) Our method does not require the use of specific reagents, such as Phoxime resin [15] or MeO-PEG-CH2CH2NH2,[16] which are rather expensive polymers used as leaving groups to facilitate the cyclization step. Likewise, aminoisocyanates, used by Beauchemin et al. [10] as reagents to prepare 3-aminohydantoins, are not readily available.[23]
In summary, we have developed a new method for the synthesis of 3-aminohydantoins in two steps, relying on the use of available and low-cost reagents, such as α-amino esters, together with hydrazine hydrate or simple arylhydrazines. This method provides a variety of substituted and nonsubstituted 3-aminohydantoins in moderate to good yields and appears a simpler and more practical method than the previously disclosed ones. This method will allow easier access to 3-aminohydantoins in order to exploit them in the field of medicinal chemistry. Further work taking advantage of this method is under way and will be reported in due course.
#
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgment
Université de Monastir (Tunisia) and Université Laval (Québec, Canada) are acknowledged for providing research facilities.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/a-2217-6821.
- Supporting Information
-
References and Notes
- 1 Meusel M, Gutschow M. Org. Prep. Proced. Int. 2004; 36: 391
- 2 Caldwell AG, Harris CJ, Stepney R, Whittaker N. J. Chem. Soc., Perkin Trans. 1 1980; 495
- 3 Wessels FL, Schwan TJ, Pong SF. J. Pharm. Sci. 1980; 69: 1102
- 4 Thenmozhiyal JC, Wong PT.-H, Chui W.-K. J. Med. Chem. 2004; 47: 1527
- 5 Konnert L, Lamaty F, Martinez J, Colacino E. Chem. Rev. 2017; 117: 13757
- 6 Tung JS, Guinn AC, Thorsett G, Pleiss MA. WO03/064396 A1, 2003
- 7 Beard RL, Vu T, Donello JE, Viswanath V, Garst ME. WO2013/071203 A1, 2013
- 8 Nakamura T, Takagi M, Ueda N. WO2003/037864, 2003
- 9 Todorov PT, Naydenova ED, Troev KD. Heteroat. Chem. 2009; 20: 87
- 10 Vincent-Rocan J.-F, Clavette C, Leckett K, Beauchemin AM. Chem. Eur. J. 2015; 21: 3886
- 11 Mani S, Bouchnak H, Pradeloux S, Kraiem J, Soulet D, Messaoudi I. Clin. Exp. Pharmacol. Physiol. 2023; 50: 728
- 12 Lalezari I. J. Heterocycl. Chem. 1985; 22: 741
- 13 Yousong N, Min Z, Yangguang G, Fei D, Hang L, Yongmin Z, Xianran H. Bull. Korean Chem. Soc. 2002; 23: 1836
- 14 Myung-Sook P, Eun-Sung C, Myung-Sook L, Soon-Kyoung K. Med. Chem. Res. 2015; 24: 4207
- 15 Hamuro Y, Marshall WJ, Scialdone MA. J. Comb. Chem. 1999; 1: 163
- 16 Yoon J, Cho C-W, Han H, Janda KD. Chem. Commun. 1998; 2703
- 17 Tsai JH, Takaoka LR, Powell NA, Nowick JS. Org. Synth. 2002; 78: 220
- 18 Typical Procedure for the Synthesis of Isocyanates 2a–f A mixture of phenylalanine methyl ester hydrochloride (1a, 4.30 g, 20 mmol) and triphosgene (BTC) (1.98 g, 6.66 mmol) in saturated aqueous sodium bicarbonate (100 mL) and dichloromethane (100 mL) was stirred in an ice bath for 0.5 h and then poured into a 500 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined organic layers were dried (MgSO4), and the solvent was evaporated under reduced pressure to afford quantitatively the corresponding isocyanate 2a. The isocyanate was used in the next step without further purification.Methyl 2-Isocyanato-3-phenylpropanoate (2a)The product was isolated as colorless oil (3.88 g, 19.0 mmol, 95%). IR (KBr): 2257, 1747 cm–1. 1H NMR (400 MHz, CDCl3): δ = 7.38–7.30 (m, 3 H), 7.23 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 2 H), 4.29 (dd, J1 =7.6 Hz, J2 = 4.4 Hz, 1 H), 3.80 (s, 3 H), 3.17 (dd, J1 = 13.6 Hz, J2 = 4.4 Hz, 2 H), 3.05 (dd, J1 = 13.6 Hz, J2 = 7.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ = 171.0, 135.6, 129.3, 128.6, 127.4, 126.5, 58.5, 53.1, 39.8.
- 19 Nowick JS, Holmes DL, Noronha G, Smith EM, Nguyen TM, Huang S.-L. J. Org. Chem. 1996; 61: 3929
- 20 Castellano RK, Nuckolls C, Rebek J. J. Am. Chem. Soc. 1999; 121: 11156
- 21 Ulatowski F, Jurczak J. Tetrahedron: Asymmetry 2014; 25: 962
- 22 Experimental Procedure and Characterization DataIsocyanate 2 (5 mmol), hydrazine hydrate (0.25 mL, 5 mmol), DIPEA (2.55 mL, 15 mmol), and DMAP (0.122 g, 1 mmol) were dissolved in anhydrous dimethyl sulfoxide (2 mL). The mixture was stirred for 0.5 h at 0 °C and then heated for 0.5 h at 100 °C in a pressure tube. The progress of the reaction was monitored by TLC. After cooling the reaction mixture to room temperature, the product was precipitated by adding diethyl ether (5 mL). The precipitate was then filtered and purified by flash chromatography using CH2Cl2/MeOH (90:10) as the eluent. 5-[2-(Methylthio)ethyl]-3-(phenylamino)imidazolidine-2,4-dione (4f)According to the general procedure, the product was isolated as white solid (0.966 g, 3.6 mmol, 73%); Rf = 0.44 (CH2Cl2/CH3OH, 95:5); mp 164–166 °C. IR (KBr): 3359, 3108, 1778, 1732 cm–1. 1H NMR (500 MHz, DMSO-d 6): δ = 8.52 (s, 1 H, Ph–NH), 8.34 (s, 1 H, NH–CO), 7.22–6.67 (m, 5 H, Ph), 4.37 (dd, J1 = 6.8 Hz, J2 = 5.0 Hz, 1 H, CH–CH2), 2.62 (m, 2 H, S–CH2), 2.07 (s, 3 H, CH3–S), 1.90 (m, 2 H, CH2–CH). 13C NMR (125 MHz, DMSO-d 6): δ = 173.0, 155.6, 147.2, 129.3, 120.0, 112.5, 54.3, 31.6, 29.1, 15.0. HRMS: m/z calcd for C12H15N3O2S [M+]: 266.0959; found [M + H+]: 266.0958.
- 23 Beauchemin AM, Clavette C, Gan W, Markiewicz T, Toderian AB. WO2013/067646 A1, 2013
Corresponding Authors
Publication History
Received: 17 October 2023
Accepted after revision: 22 November 2023
Accepted Manuscript online:
24 November 2023
Article published online:
11 December 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References and Notes
- 1 Meusel M, Gutschow M. Org. Prep. Proced. Int. 2004; 36: 391
- 2 Caldwell AG, Harris CJ, Stepney R, Whittaker N. J. Chem. Soc., Perkin Trans. 1 1980; 495
- 3 Wessels FL, Schwan TJ, Pong SF. J. Pharm. Sci. 1980; 69: 1102
- 4 Thenmozhiyal JC, Wong PT.-H, Chui W.-K. J. Med. Chem. 2004; 47: 1527
- 5 Konnert L, Lamaty F, Martinez J, Colacino E. Chem. Rev. 2017; 117: 13757
- 6 Tung JS, Guinn AC, Thorsett G, Pleiss MA. WO03/064396 A1, 2003
- 7 Beard RL, Vu T, Donello JE, Viswanath V, Garst ME. WO2013/071203 A1, 2013
- 8 Nakamura T, Takagi M, Ueda N. WO2003/037864, 2003
- 9 Todorov PT, Naydenova ED, Troev KD. Heteroat. Chem. 2009; 20: 87
- 10 Vincent-Rocan J.-F, Clavette C, Leckett K, Beauchemin AM. Chem. Eur. J. 2015; 21: 3886
- 11 Mani S, Bouchnak H, Pradeloux S, Kraiem J, Soulet D, Messaoudi I. Clin. Exp. Pharmacol. Physiol. 2023; 50: 728
- 12 Lalezari I. J. Heterocycl. Chem. 1985; 22: 741
- 13 Yousong N, Min Z, Yangguang G, Fei D, Hang L, Yongmin Z, Xianran H. Bull. Korean Chem. Soc. 2002; 23: 1836
- 14 Myung-Sook P, Eun-Sung C, Myung-Sook L, Soon-Kyoung K. Med. Chem. Res. 2015; 24: 4207
- 15 Hamuro Y, Marshall WJ, Scialdone MA. J. Comb. Chem. 1999; 1: 163
- 16 Yoon J, Cho C-W, Han H, Janda KD. Chem. Commun. 1998; 2703
- 17 Tsai JH, Takaoka LR, Powell NA, Nowick JS. Org. Synth. 2002; 78: 220
- 18 Typical Procedure for the Synthesis of Isocyanates 2a–f A mixture of phenylalanine methyl ester hydrochloride (1a, 4.30 g, 20 mmol) and triphosgene (BTC) (1.98 g, 6.66 mmol) in saturated aqueous sodium bicarbonate (100 mL) and dichloromethane (100 mL) was stirred in an ice bath for 0.5 h and then poured into a 500 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined organic layers were dried (MgSO4), and the solvent was evaporated under reduced pressure to afford quantitatively the corresponding isocyanate 2a. The isocyanate was used in the next step without further purification.Methyl 2-Isocyanato-3-phenylpropanoate (2a)The product was isolated as colorless oil (3.88 g, 19.0 mmol, 95%). IR (KBr): 2257, 1747 cm–1. 1H NMR (400 MHz, CDCl3): δ = 7.38–7.30 (m, 3 H), 7.23 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 2 H), 4.29 (dd, J1 =7.6 Hz, J2 = 4.4 Hz, 1 H), 3.80 (s, 3 H), 3.17 (dd, J1 = 13.6 Hz, J2 = 4.4 Hz, 2 H), 3.05 (dd, J1 = 13.6 Hz, J2 = 7.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ = 171.0, 135.6, 129.3, 128.6, 127.4, 126.5, 58.5, 53.1, 39.8.
- 19 Nowick JS, Holmes DL, Noronha G, Smith EM, Nguyen TM, Huang S.-L. J. Org. Chem. 1996; 61: 3929
- 20 Castellano RK, Nuckolls C, Rebek J. J. Am. Chem. Soc. 1999; 121: 11156
- 21 Ulatowski F, Jurczak J. Tetrahedron: Asymmetry 2014; 25: 962
- 22 Experimental Procedure and Characterization DataIsocyanate 2 (5 mmol), hydrazine hydrate (0.25 mL, 5 mmol), DIPEA (2.55 mL, 15 mmol), and DMAP (0.122 g, 1 mmol) were dissolved in anhydrous dimethyl sulfoxide (2 mL). The mixture was stirred for 0.5 h at 0 °C and then heated for 0.5 h at 100 °C in a pressure tube. The progress of the reaction was monitored by TLC. After cooling the reaction mixture to room temperature, the product was precipitated by adding diethyl ether (5 mL). The precipitate was then filtered and purified by flash chromatography using CH2Cl2/MeOH (90:10) as the eluent. 5-[2-(Methylthio)ethyl]-3-(phenylamino)imidazolidine-2,4-dione (4f)According to the general procedure, the product was isolated as white solid (0.966 g, 3.6 mmol, 73%); Rf = 0.44 (CH2Cl2/CH3OH, 95:5); mp 164–166 °C. IR (KBr): 3359, 3108, 1778, 1732 cm–1. 1H NMR (500 MHz, DMSO-d 6): δ = 8.52 (s, 1 H, Ph–NH), 8.34 (s, 1 H, NH–CO), 7.22–6.67 (m, 5 H, Ph), 4.37 (dd, J1 = 6.8 Hz, J2 = 5.0 Hz, 1 H, CH–CH2), 2.62 (m, 2 H, S–CH2), 2.07 (s, 3 H, CH3–S), 1.90 (m, 2 H, CH2–CH). 13C NMR (125 MHz, DMSO-d 6): δ = 173.0, 155.6, 147.2, 129.3, 120.0, 112.5, 54.3, 31.6, 29.1, 15.0. HRMS: m/z calcd for C12H15N3O2S [M+]: 266.0959; found [M + H+]: 266.0958.
- 23 Beauchemin AM, Clavette C, Gan W, Markiewicz T, Toderian AB. WO2013/067646 A1, 2013
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_f1_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s1_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s2_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202304/thumbnails/i_t0077_s3_10-1055_a-2217-6821.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)